###begin article-title 0
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
Simultaneous identification of GSTP1 Ile105-->Val105 and Ala114-->Val114 substitutions using an amplification refractory mutation systempolymerase chain reactionassay: studies in patients with asthma
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 388 389 384 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 383 390 379 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>A</italic>
###xml 425 426 419 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 420 427 414 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>B</italic>
###xml 452 453 444 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 447 454 439 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>C</italic>
###xml 482 483 472 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 477 484 467 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>D</italic>
The glutathione S-transferase (GST) enzyme GSTP1 utilizes byproducts of oxidative stress. We previously showed that alleles of GSTP1 that encode the Ile105-->Val105 substitution are associated with the asthma phenotypes of atopy and bronchial hyperresponsiveness (BHR). However, a further polymorphic site (Ala114-->Val114) has been identified that results in the following alleles: GSTP1*A (wild-type Ile105-->Ala114), GSTP1*B (Val105-->Ala114), GSTP1*C (Val105-->Val114) and GSTP1*D (Ile105-->Val114).
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
Because full identification of GSTP1 alleles may identify stronger links with asthma phenotypes, we describe an amplification refractory mutation system (ARMS) assay that allows identification of all genotypes. We explored whether the GSTP1 substitutions influence susceptibility to asthma, atopy and BHR.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 193 194 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 297 302 297 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 339 340 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 379 384 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
Among 191 atopic nonasthmatic, atopic asthmatic and nonatopic nonasthmatic individuals, none had the BD, CD, or DD genotypes. GSTP1 BC was significantly associated with reduced risk for atopy (P = 0.031). Compared with AA, trend test analysis identified a significant decrease in the frequency of GSTP1 BC with increasing severity of BHR (P = 0.031). Similarly, the frequency of GSTP1 AA increased with increasing BHR.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 24 31 24 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>B</italic>
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 45 52 45 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>C</italic>
These data suggest that GSTP1*B and possibly GSTP1*C are protective against asthma and related phenotypes.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 683 684 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 193 198 <span type="species:ncbi:9606">human</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
Polymorphisms in members of the GST supergene family have been associated with individual susceptibility to lung diseases [1]. In the context of asthma GSTP1 - the predominant GST expressed in human lung [2] - is a candidate because this enzyme has a role in cellular protection against oxidative stress [3]. Thus, GSTP1 catalyzes the detoxification of byproducts of lipid and DNA oxidation [1]. Asthma is characterized by airway inflammation [4]. Indeed, BHR reflects the presence of inflammation, and is exhibited by virtually all asthmatic patients. Atopic individuals (as defined by serum IgE levels and skin prick tests) are very likely to have increased airway responsiveness [4]. Thus, studies designed to identify susceptibility genes for asthma must consider the possible interrelationship of BHR and atopy in the expression of the asthma phenotype.
###end p 10
###begin p 11
###xml 62 67 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 113 114 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 243 248 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 351 352 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 346 353 342 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>A</italic>
###xml 378 379 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 373 380 367 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>B</italic>
###xml 405 406 397 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 400 407 392 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>C</italic>
###xml 435 436 425 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 430 437 420 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>D</italic>
###xml 457 458 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 459 460 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 461 462 449 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 463 464 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 591 592 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 711 712 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 713 714 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 715 716 703 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 717 719 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 720 722 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 856 858 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
We previously showed that the Ile105-->Val105 substitution in GSTP1 is strongly associated with severity of BHR [5]. A further polymorphism is present at amino acid 114 (Ala114-->Val114), however, indicating that unequivocal identification of GSTP1 alleles requires consideration of both substitutions. These polymorphisms give rise to wild-type GSTP1*A (Ile105-->Ala114), GSTP1*B (Val105-->Ala114), GSTP1*C (Val105-->Val114) and GSTP1*D (Ile105-->Val114) [6,7,8,9]. Although the Ile105 variant has a higher catalytic efficiency for 1-chloro-2,4-dinitrobenzene than does the Val105 variant [6], the Val105 variant appears to confer higher catalytic efficiency for polycyclic aromatic hydrocarbon diol epoxides [7,8,9,10,11]. The effect of the Ala114-->Val114 substitution is unclear, although it may enhance the effect of the Ile105-->Val105 substitution [11].
###end p 11
###begin p 12
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 476 483 <span type="species:ncbi:9606">persons</span>
Because the substitution at amino acid 114 may modify the association of GSTP1 Ile105-->Val105 with asthma phenotypes, we developed an ARMS assay in order to identify unambiguously those genotypes that result from the A, B, C and D alleles. This approach is necessary, because presently described assays do not differentiate AC and BD genotypes. We also determined the frequencies of these genotypes in atopic nonasthmatic, atopic asthmatic and nonatopic nonasthmatic healthy persons.
###end p 12
###begin title 13
Materials and methods
###end title 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 14
###begin p 15
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 317 318 317 318 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 353 355 353 355 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 430 431 430 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 465 467 465 467 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 547 548 547 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 662 663 662 663 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 667 669 667 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 759 760 759 760 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 93 100 <span type="species:ncbi:9606">persons</span>
###xml 1072 1075 <span type="species:ncbi:9685">cat</span>
###xml 1081 1084 <span type="species:ncbi:9615">dog</span>
###xml 1266 1278 <span type="species:ncbi:9606">participants</span>
Unrelated Northern European nonatopic nonasthmatic, atopic nonasthmatic and atopic asthmatic persons (n = 191) were recruited in North Staffordshire, UK [5]. They were stratified by degree of airway reactivity/obstruction as follows (Table 1): group 1, BHR negative (normal), with forced expiratory volume in 1 s (FEV1) greater than 80% predicted and PC20 greater than 16 mg/ml metacholine; group 2, borderline BHR (mild) with FEV1 greater than 80% predicted and PC20 positive with 8-16 mg/ml metacholine; group 3, BHR positive (moderate) with FEV1 greater than 80% predicted and provoking concentration of an inhaled substance that causes a 20% reduction in FEV1 (PC20) positive with 0.03-8 mg/ml metacholine; and group 4, severe airway dysfunction, with FEV1 of 80% or less than predicted, which was not challenged with metacholine for ethical reasons. A positive skin reaction (mean wheal diameter of at least 3 mm more than with saline control) in response to at least one of a panel of seven common aeroallergens (house dust mite, house dust, grass mix, tree pollen, cat fur, dog fur, feathers) and serum IgE levels greater than 100 IU/ml were used to define atopic status, together with personal history. The local Ethics Committee approved the study, and all participants provided written informed consent.
###end p 15
###begin p 16
Clinical parameters of recruited subjects
###end p 16
###begin p 17
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 249 255 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 264 265 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 9 17 <span type="species:ncbi:9606">patients</span>
*In some patients we were unable to obtain a complete data set. Some individuals were unwilling to undertake a metacholine challenge test, whereas others did not wish to donate a blood sample (in this case DNA was isolated from a mouthwash sample). dagger Mean FEV1 = 67% predicted (min = 45%, max = 78%).
###end p 17
###begin title 18
Determination of GSTP1 genotypes
###end title 18
###begin p 19
###xml 143 144 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 145 147 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 220 225 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 227 229 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 286 291 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
Genotyping was performed using leucocyte DNA. The Ile105-->Val105 substitution was identified using primers to exon 5 as previously described [7,12]. The Ala114-->Val114 substitution was identified as described by Board et al [13], with an annealing temperature of 65degreesC. However, GSTP1 AC and BD gave heterozygous patterns using both of the above assays. An ARMS assay was therefore developed to differentiate between these genotypes. This included a forward primer upstream of the codon 105 substitution (5'-ACCCCAGGGCTC-TATGGGAA-3') and two reverse primers (primer A [Ala114 specific], 5'-TCACATAGTCATCCTTGCCGG-3'; and primer B [Val114 specific], 5'-TCACATAGTCATC-CTTGCCGA-3').
###end p 19
###begin p 20
###xml 366 367 363 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
For each DNA sample two polymerase chain reactions (PCRs) were performed, amplifying a 998 base pair fragment. PCRs were carried out in 50 mul containing forward primer, reverse primer A or B (2 x 0.25 mumol/l), Taq polymerase (1 U), dNTP (4 x 200 mumol/l), 1 x polymerase buffer (10 mmol/l Tris-HCl pH9.0, 50 mmol/l KCl, 0.1% [vol/vol] Triton X-100, 1.5 mmol/l MgCl2), and target DNA (approximately 0.5 mug). Conditions were as follows: 94degreesC for 4 min, 30 cycles of denaturation (94degreesC, 1 min), primer annealing (62degreesC, 1 min) and elongation (72degreesC, 2 min).
###end p 20
###begin p 21
###xml 323 326 321 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bsm</italic>
###xml 347 350 345 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 351 356 349 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 727 728 723 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 82 89 <span type="species:ncbi:9606">persons</span>
###xml 178 185 <span type="species:ncbi:9606">persons</span>
The initial ARMS PCR was used to determine the Ala114-->Val114 genotype. Thus, in persons with Ala114/Ala114 amplification occurred only with primer A, and only with primer B in persons with Val114/Val114; for Ala114/Val114 heterozygotes, amplification occurred with both primers. ARMS PCR products were then digested with Bsm AI to determine the cis/trans configuration (which variant at position 105 is paired with which allele at position 114) of the Ile105-->Val105 encoding allele and resolved in 2% (vol/weight) agarose gels. Products gave fragments of 343, 322, 260 and 73 base pairs with Ile105/Ile105; 93, 250, 322, 260 and 73 base pairs with Val105/Val105; and all six fragments in heterozygotes (Ile105/Val105; Fig. 1).
###end p 21
###begin p 22
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bsm</italic>
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
Illustration of the sites of primers and Bsm AI restriction endonuclease maps of the variant GSTP1, together with the banding patterns obtained from the ARMS assay for each genotype. Products gave fragments of 343, 322, 260 and 73 base pairs with Ile105/Ile105; 93, 250, 322, 260 and 73 base pairs with the Val105/Val105; and all six fragments in heterozygotes (Ile105/Val105). Base pair numbering according to Morrow et al [21].
###end p 22
###begin p 23
Every run (including both restriction fragment length polymorphism and ARMS assays) included DNA samples of known genotype as positive controls and one negative control (no DNA). Samples with AA (Ala114/Ala114) and CC (Val114/Val114) were used to optimize the procedure, and as controls for the ARMS PCR. As an assessment of quality control, approximately 15% of DNA samples were reassayed at least once in order to confirm the assigned genotype. All results from the reassayed samples were consistent with the original genotype assignment.
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
###xml 3 4 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
chi2 tests were used to assess homogeneity between groups (eg skin test positive versus skin test negative). As some allele frequencies were small, the StatXact-Turbo (version 3; Cytel Software Corporation, Cambridge, MA, USA) statistical package was used when appropriate. All other statistical analyses were performed using the Stata statistical package (version 6; Stata Corporation, College Station, TX, USA). In order to correct for imbalances in age and sex between groups, logistic regression was used. The Armitage trend test was used to examine the relationship between genotypes and ordered categories (eg degree of BHR). In order to correct these trend test analyses for potential confounding factors such as age and sex, ordered logistic regression models were applied.
###end p 25
###begin title 26
Results
###end title 26
###begin title 27
Determination of GSTP1 genotypes
###end title 27
###begin p 28
###xml 187 192 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 314 315 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Using the two PCR assays it was possible to identify all genotypes unambiguously, except 24 heterozygotes for the Ile105-->Val105 and Ala114-->Val114 substitutions, which could have been GSTP1 AC or BD. Accordingly, ARMS PCR was used to identify these genotypes. Banding patterns are shown in Supplementary Figure 2.
###end p 28
###begin p 29
###xml 226 229 226 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bsm</italic>
Lanes 1, 3, 5, 7 and 9 include the amplified product from Ala114 specific primer, whereas lanes 2, 4, 6, 8 and 10 include the product from the Val114 specific primer. PCR products from either primer give, after digestion with Bsm AI, fragments of either 343, 322, 260 and 73 base pairs for the Ile105 allele, or 322, 260, 250, 93 and 73 base pairs for the Val105 allele. Lane 11, molecular weight markers, pBR HaeIII. PCR products were visualized in 2% agarose gels.
###end p 29
###begin p 30
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 121 128 121 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>D</italic>
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 253 254 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 267 268 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 268 269 266 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 64 71 <span type="species:ncbi:9606">persons</span>
The frequencies of GSTP1 genotypes are shown in Table 2. In 191 persons, none had BD, CD or DD, reflecting the rarity of GSTP1*D. The frequencies of GSTP1 genotypes achieved Hardy-Weinberg equilibrium. As reported previously [14], we found significant (P <0.0001, chi24 = 50.9) linkage disequilibrium between Ile105 and Ala114 and between Val105 and Val114.
###end p 30
###begin p 31
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
The association ofGSTP1 genotype with atopic status and degree of airway reactivity/obstruction
###end p 31
###begin p 32
###xml 144 146 144 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 195 197 195 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 247 249 247 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 414 415 412 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 471 476 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 487 492 485 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 524 525 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 594 595 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 657 662 655 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 673 678 671 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 682 683 680 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 724 725 722 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Atopic status was defined as positive skin test and IgE 100 IU/ml or less. Groups were defined as follows: group 1, percentage predicted >80%/PC20 >16 mg/ml; group 2, percentage predicted >80%/PC20 8-16 mg/ml; group 3, percentage predicted >80%/PC20 0-8 mg/ml; and group 4, percentage predicted </= 80%. Values are expressed as number (%) for the genotype frequencies, or as proportions for the allele frequencies.*Logistic regression analysis for skin test: uncorrected GSTP1 BC versus GSTP1 AA, OR 0.17, 95% CI 0.03-0.85 (P = 0.031); and corrected for age and sex, OR 0.18, 95% CI 0.04-0.96 (P = 0.045). Trend test analysis across groups 1-4: uncorrected GSTP1 BC versus GSTP1AA, P = 0.031; and corrected for age and sex, P = 0.02.
###end p 32
###begin title 33
Association of GSTP1 genotype with atopic indices
###end title 33
###begin p 34
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 431 432 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 483 488 483 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 557 558 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 574 575 574 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 625 630 625 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 691 692 691 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 686 693 686 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>B</italic>
###xml 375 382 <span type="species:ncbi:9606">persons</span>
Table 2 shows the association of GSTP1 genotypes with skin test positivity or IgE level. The frequencies of GSTP1 BB and BC were reduced in individuals with at least one positive skin test (2.5 and 1.7%, respectively) as compared with individuals who were skin test negative (5.6 and 9.9%, respectively). Although the frequency of GSTP1 BB was not significantly lower in the persons with positive skin tests (odds ratio [OR] 0.44; P = 0.297) or with IgE levels of 100 IU/ml or less, GSTP1 BC was significantly associated with skin test negativity (OR 0.17; P = 0.031; Table 2). There were no significant associations between GSTP1 genotypes and IgE level, although all individuals with GSTP1*B had IgE levels of 100 IU/ml or less.
###end p 34
###begin title 35
Association of GSTP1 genotypes with airway obstruction/reactivity
###end title 35
###begin p 36
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 356 361 356 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 370 375 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 451 452 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 562 563 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Table 2 shows the frequencies of GSTP1 genotypes in relation to degree of airflow obstruction and BHR. The GSTP1 AA frequency increased with severity of airway reactivity/obstruction, whereas BB and BC frequencies displayed a reverse trend. Compared with GSTP1 AA, trend test analysis across the four groups revealed a significant decrease in frequency of GSTP1 BC (and GSTP1 BB, albeit not significant) with increasing airway reactivity/obstruction (P = 0.031), indicating a protective effect. This effect remained significant after correction for age and sex (P = 0.022) using ordered logistic regression analysis.
###end p 36
###begin title 37
Association of GSTP1 genotype with presence of asthma
###end title 37
###begin p 38
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 241 246 241 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 338 343 338 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 483 488 483 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 620 621 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 731 732 731 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
We further examined the association of GSTP1 genotypes with the clinical presence of asthma, as defined using the recognized cutoff of <8 mg/ml methacholine [15] on bronchial challenge (groups1 and 2 versus groups 3 and 4). The frequency of GSTP1 AA was increased in groups3 and 4 (44.9%) as compared with groups 1 and 2 (28.8%), whereas GSTP1 BB and BC frequencies were lower in groups 3 and 4 (2.0 and 2.0%, respectively) than in groups 1 and 2 (5.5 and 8.2%, respectively). Thus, GSTP1 BC was associated with a sixfold reduction in asthma risk compared with GSTP1 AA (OR 0.16, 95% confidence interval [CI] 0.03-0.86; P = 0.032). This association remained significant after correction for age and sex (OR 0.15, 95% CI 0.03-0.80; P = 0.027).
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 321 326 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
We showed that the 105 substitution in GSTP1 is associated with atopy and BHR [5]. We have now extended these observations by examining whether the 114 substitution modulates this effect. We determined the GSTP1 genotype using two reported PCR assays for each polymorphic site. However, these assays do not differentiate GSTP1 AC and BD. Accordingly, we developed an ARMS assay to allow identification of all genotypes.
###end p 40
###begin p 41
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 509 514 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 676 681 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
GSTP1 is of particular interest in asthma, because chromosome 11q13 is associated with its clinical phenotypes: atopy and BHR [16]. Several candidates (high affinity IgE receptor, clara cell secretory protein) have been identified, although the encoding genes do not account for the strength of the linkage to this region [16]. We proposed that GSTP1 is another candidate gene in this region [17], although it is of course possible that another gene may be the target, and that the observed associations with GSTP1 genotype reflect linkage disequilibrium with this gene. Thus, the efficiency of detoxification of reactive oxygen species products determined by polymorphism in GSTP1 may influence the development and/or severity of BHR and asthma.
###end p 41
###begin p 42
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 426 431 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
We found that the frequency of GSTP1 AA was increased in patients with established asthma. Similar findings have been found in other proinflammatory conditions, such as chronic obstructive pulmonary disease [18] and multiple sclerosis [19]. However, studies in rheumatoid arthritis [20] and basal cell carcinoma [12] show that GSTP1 Ile105/Ile105 is protective, whereas Val105/Val105 is associated with a worse outcome. Thus, GSTP1-associated risk is likely to be disease-dependent, possibly reflecting differences in relevant substrates.
###end p 42
###begin p 43
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 99 106 <span type="species:ncbi:9606">persons</span>
The data reported here also show that the frequencies of GSTP1 BC and BB were reduced in asthmatic persons, thus indicating a protective effect. This supports the view that there is little additional effect on disease risk from the Ala114-->Val114 substitution, although the number of individuals with some genotypes was small and larger numbers would be required to confirm this observation. The advantage with using this ARMS assay is that it is possible to discriminate between genotypes AC and BD. It relies on a relatively large fragment (998 base pairs), however, and is therefore not suitable for genotyping of archival DNA. Thus, this technique is applicable for studies into population genetics.
###end p 43
###begin p 44
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 212 213 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 207 214 207 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>B</italic>
###xml 224 225 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 219 226 219 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>C</italic>
###xml 351 352 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 346 362 346 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>B, GSTP1<sup>*</sup>C</italic>
###xml 372 373 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 367 374 367 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1<sup>*</sup>D</italic>
###xml 277 284 <span type="species:ncbi:9606">patient</span>
In conclusion, we described an ARMS assay to identify genotypes resulting from the A, B, C and D alleles of GSTP1, and provided data on the effect of GSTP1 genotype on asthma risk. Our findings suggest that GSTP1*B and GSTP1*C confer similar protective effects. However, large patient groups are required to identify differential effects between GSTP1*B, GSTP1*C and GSTP1*D.
###end p 44
###begin title 45
Abbreviations
###end title 45
###begin p 46
###xml 115 116 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 204 206 204 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 291 292 291 292 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
ARMS = amplification refractory mutation system; BHR = bronchial hyperresponsiveness; CI = confidence interval; FEV1 = forced expiratory volume in 1 s; GST = glutathione S-transferase; OR = odds ratio; PC20 = provoking concentration of an inhaled substance that causes a 20% reduction in FEV1; PCR = polymerase chain reaction.
###end p 46
###begin title 47
Acknowledgements
###end title 47
###begin p 48
Supported by the British Lung Foundation (Project Grant P99/15) and the Danish Research Academy (Project Grant 0000120).
###end p 48
###begin article-title 49
Glutathione S-transferase polymorphisms and their biological concequences.
###end article-title 49
###begin article-title 50
###xml 86 91 <span type="species:ncbi:9606">human</span>
The development of glutathione S-transferase and glutathione peroxidase activities in human lung.
###end article-title 50
###begin article-title 51
###xml 131 136 <span type="species:ncbi:9606">human</span>
Detoxification of base propenals and other alpha,beta-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases.
###end article-title 51
###begin article-title 52
Issues in phenotype assessment.
###end article-title 52
###begin article-title 53
Polymorphism at the glutathione S-transferase, GSTP1 locus: a new marker for bronchial hyperresponsiveness and asthma.
###end article-title 53
###begin article-title 54
###xml 55 71 55 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 55 71 <span type="species:ncbi:562">Escherichia coli</span>
###xml 102 107 <span type="species:ncbi:9606">human</span>
Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants.
###end article-title 54
###begin article-title 55
Identification of genetic polymorphism at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer.
###end article-title 55
###begin article-title 56
Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocorbons.
###end article-title 56
###begin article-title 57
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution.
###end article-title 57
###begin article-title 58
###xml 18 23 <span type="species:ncbi:9606">human</span>
Natural occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties.
###end article-title 58
###begin article-title 59
###xml 49 54 <span type="species:ncbi:9606">human</span>
Active site architecture of polymorphic forms of human glutathione S-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione conjugation of 7beta,8alpha-dihydroxy-9alpha,10alpha-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene.
###end article-title 59
###begin article-title 60
###xml 113 120 <span type="species:ncbi:9606">patient</span>
Glutathione S-transferase GSTP1 and cyclin D1 genotypes: associations with numbers of basal cell carcinomas in a patient subgroup at high-risk of multiple tumours.
###end article-title 60
###begin article-title 61
Genetic heterogeneity of the structure and function of GSTT2 and GSTP1.
###end article-title 61
###begin article-title 62
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients.
###end article-title 62
###begin article-title 63
Bronchial responsiveness in active steelworkers.
###end article-title 63
###begin article-title 64
The candidate region approach to the genetics of asthma and allergy.
###end article-title 64
###begin article-title 65
Polymorphisms at the Glutathione S-transferase, GSTP1 locus: a novel mechanism for susceptibility and development of atopic airway inflammation.
###end article-title 65
###begin article-title 66
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease.
###end article-title 66
###begin article-title 67
Glutathione S-transferase polymorphisms in multiple sclerosis. Their relationship to disability.
###end article-title 67
###begin article-title 68
Association of polymorphism in glutathione S-transferase loci with susceptibility and outcome in rheumatoid arthritis: comparison with the shared epitope.
###end article-title 68
###begin article-title 69
###xml 17 22 <span type="species:ncbi:9606">human</span>
Structure of the human genomic glutathione S-transferase-pi gene.
###end article-title 69

